Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Aimed at improving patient outcomes and increasing connectivity for more efficient monitoring In hospitals and homes
The virtual event will be attended by representatives from state & district health administration, corporates, industries, civil society, and NGOs as the country reiterates its commitment towards TB elimination by 2025
In a rare occurrence worldwide, the CK Birla Hospital® treats 32-year-old woman for a giant mesenteric tumour via complex laparoscopic surgery
Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
The purpose of the conclave was to discuss the present situation of body-organ-eye donation in India and find solutions to the challenges ahead in future
Subscribe To Our Newsletter & Stay Updated